The Use of Smoking Cessation Applications in China: A Realist Evaluation
Studies in Health Technology and Informatics · 2025
DOI: 10.3233/shti250528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Studies in Health Technology and Informatics, 2025. Verfasst von Mengying Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Health in Social Science, The University of Edinburgh, UK. Hauptthemen laut MEDLINE: Smoking Cessation, Mobile Applications. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Mobile applications (apps) have emerged as promising tools for smoking cessation, though limited research has explored how these apps work. This study employed a realist evaluation approach to develop programme theories that explain how, why and under which circumstances smoking cessation apps work. Initial programme theories (IPTs) were formulated and tested and subsequently refined. The refined programme theories can be useful resources for app developers to design smoking cessation apps that better meet user needs in their pursuit to quit smoking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Health in Social Science, The University of Edinburgh, UK.
- School of Informatics, University of Edinburgh, UK.
Zitieren
APA
Zhang, M., Doi, L., Wolters, M., & Clarissa, C. (2025). The Use of Smoking Cessation Applications in China: A Realist Evaluation. Studies in Health Technology and Informatics. https://doi.org/10.3233/shti250528
Vancouver
Zhang M, Doi L, Wolters M, Clarissa C. The Use of Smoking Cessation Applications in China: A Realist Evaluation. Studies in Health Technology and Informatics. 2025. doi:10.3233/shti250528
BibTeX
@article{Zhang2025,
author = {Zhang, Mengying and Doi, Lawrence and Wolters, Maria and Clarissa, Catherine},
title = {The Use of Smoking Cessation Applications in China: A Realist Evaluation},
journal = {Studies in Health Technology and Informatics},
year = {2025},
doi = {10.3233/shti250528}
}
EUVIMED